A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Study Summary

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Conditions

Lupus Erythematosus, Systemic Lupus Nephritis

Interventions / Drugs

CC-97540 Fludarabine Cyclophosphamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment89 participants

Primary Completion—

Lead SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Data Retrieved2026-04-11 04:08:14.746714+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.